Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 25Breast 25Thoracic 8Sarcoma 4Head & Neck 4Tumor-Agnostic 3Lymphoid 3Gynecologic 3Genitourinary 3CNS 2Plasma cell 1Other solid neoplasm 1Endocrine 1Dermatologic 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoadjuvant Therapy × Tumor-Agnostic × 1 year × Clear all
NCT06417190 2026-05-04

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Cedars-Sinai Medical Center

Phase 2 Recruiting
20 enrolled
Tumor-Agnostic

Neoplasms

NCT02212860 2026-02-11

SIGNAL 2

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase NA Completed
139 enrolled
Tumor-Agnostic

Neoplasms

NCT06831136 2025-09-10

PANCARDINAL-2

The University of Texas Health Science Center, Houston

Phase 2 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡